Compare Marqeta Inc (MQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Marqeta Inc trades at $15.94 (market cap $1.66B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| MQ | XBI | |
|---|---|---|
Market Cap | $1.66B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $23.88 | $169.55 |
52-Week Low | $15.04 | $93.43 |
Enterprise Value | $970.76M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $16.26, down 1.93% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive net cash flow of $86.42M in 2025. Recent developments include expansion of Google Wallet partnership and stablecoin card initiatives. Valuation metrics remain elevated with P/E of 180.89 and EV/EBITDA of 48.53 despite modest profitability margins.
MQ offers 26% upside to consensus price target of $19.00, supported by earnings estimate revisions and strategic partnerships. Key risks include high valuation multiples, competitive payment processing landscape, and the need to sustain recent profitability improvements. Institutional sentiment leans cautious with 59% hold ratings despite recent business momentum.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
